CLINICAL TRIAL

18F fluciclovine for Neoplasm Metastasis

Waitlist Available · 18+ · All Sexes · Cleveland, OH

This study is evaluating whether a new type of imaging may help detect brain cancer.

See full description

About the trial for Neoplasm Metastasis

Eligible Conditions
Neoplasm Metastasis · Neoplasms, Second Primary · Brain Neoplasms · Tumors Metastatic to Brain

Treatment Groups

This trial involves 2 different treatments. 18F Fluciclovine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
18F fluciclovine
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Neoplasm Metastasis or one of the other 3 conditions listed above. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Previous history of solid tumor brain metastasis of any origin
Histopathological confirmation of the primary solid tumor or a metastatic site
Previous radiation therapy of brain metastatic lesion(s)
A reference lesion considered by the site investigator to be equivocal for recurrent brain metastasis
Patient requires further confirmatory diagnostic procedures to confirm brain MRI findings and is planned for craniotomy
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 days post-18F-fluciclovine administration
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 days post-18F-fluciclovine administration.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether 18F fluciclovine will improve 2 primary outcomes and 3 secondary outcomes in patients with Neoplasm Metastasis. Measurement will happen over the course of 60 days.

Sensitivity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake.
60 DAYS
Sensitivity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake compared to central histopathological analysis.
Specificity of different thresholds of lesion 18F fluciclovine uptake on visual reads.
60 DAYS
Specificity of different thresholds of lesion 18F fluciclovine uptake on visual reads compared to central histopathological analysis.
Specificity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake.
60 DAYS
Specificity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake compared to central histopathological analysis.
Sensitivity of different thresholds of lesion 18F fluciclovine uptake on visual reads .
60 DAYS
Sensitivity of different thresholds of lesion 18F fluciclovine uptake on visual reads compared to central histopathological analysis.
Treatment-emergent adverse events
2 DAYS POST-18F-FLUCICLOVINE ADMINISTRATION
Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 2 days post-18F-fluciclovine administration.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get neoplasm metastasis a year in the United States?

Approximately 1 in 1000 Caucasians diagnosed with solid tumors developed NMs with an overall 5-year survival rate of 55.7%, but varied significantly by primary site and stage of cancer. A significant proportion of these patients died early on, potentially due to distant NMs not detected during the initial screening evaluation. Strategies to earlier detect and monitor NMs and to identify high-risk patients are needed to improve quality of life and survival of persons diagnosed with cancer. Clin Cancer Res; 22(11); 2680-88. ©2016 AACR.

Anonymous Patient Answer

What are the signs of neoplasm metastasis?

It is very important to diagnose metastasis of neoplasm not only because of the necessity of surgical procedures when a neoplasm invades deep tissues. In that sense, the evaluation of medical imaging is needed to determine if the neoplasm spreads to other tissues.

Anonymous Patient Answer

What is neoplasm metastasis?

Neoplasm metastasis is an important phenomenon during the development of tumors, especially during and after the surgery procedures. The metastability of the tumor cells during or after surgery is significantly linked to the invasion ability and the production of tumor-related proteins, which make the neoplasm cells more able to invade different tissues, resulting in neoplasm metastasis. The primary cancer, neoplasm metastasis and tumor relapse were the basic features of neoplasm metastasis. The advancement of neoplasm metastasis implies the need for the development of a better imaging modality for diagnosis of neoplasm metastasis, as well as for therapy decisions for neoplasm metastasis.

Anonymous Patient Answer

What causes neoplasm metastasis?

The causes of metastatic tumors are highly variable. Metastatic disease is a multifactorial process that takes several weeks to a year or more, depending on the cancer type and the extent of dissemination. A delay in diagnosis of a neoplastic or infectious disease is a prerequisite to metastasis.

Anonymous Patient Answer

Can neoplasm metastasis be cured?

Neoplasm metastasis is not [cured] by the current therapeutic techniques. It is recommended that new anticancer drugs be developed and [approved to help] eliminate the cancer cells for a better prognosis of patients with neoplasm metastasis.

Anonymous Patient Answer

What are common treatments for neoplasm metastasis?

Targeted therapy or immunotherapy is likely to play a role in the treatment of neoplasm metastasis, especially for a long-term treatment of unresectable metastatic disease.

Anonymous Patient Answer

Have there been any new discoveries for treating neoplasm metastasis?

We are still in the middle of the fight against metastatic neoplasms. As the cancer metastasizes, it is much more difficult to treat. We can use radiotherapy to prevent the cancer from growing again, but we also need treatments to remove the cancer. In addition, adjuvant chemotherapy is crucial. We can use new drugs, which make it easier to remove the cancer from the patient. In addition we can stop the metastasized cancer from growing using new therapies.

Anonymous Patient Answer

How quickly does neoplasm metastasis spread?

If a sarcoma biopsy is taken from an extremity, bone marrow examination is required. If the bone marrow examination is not abnormal in patients with metastatic sarcoma, then patients are advised to have imaging procedures performed using CT, MR or PET scanning. Bone and intrathoracic CT scans are more accurate imaging tools than chest radiography in assessing metastasis-negative patients.

Anonymous Patient Answer

Is 18f fluciclovine typically used in combination with any other treatments?

Although the authors cannot determine causation, they suggest that 18f FU should be considered, in combination with other treatments, when patients who are receiving radiotherapy can receive an additional treatment for the same primary cancer site.

Anonymous Patient Answer

What is the average age someone gets neoplasm metastasis?

Breast cancer was the most common form of cancer that caused neoplasm metastasis in our institution. The average age breast cancer caused metastasis was 41.3. Neoplasm metastasis is likely to be more severe than what is indicated by only counting number of metastatic sites in the bone. However, it is important to realize that neoplasm metastasis can be the first indication of cancer. As such, it is critical to recognize the neoplasm metastasis as it can be indicative of the presence of earlier forms cancer in the body.

Anonymous Patient Answer

What is the survival rate for neoplasm metastasis?

According to Survival Meta-analysis for patients with neoplasm metastasis, the survival rate is [approximately] 5-years after treatment. Overall survival rate depends on metastatic location(cancer cell origin) and patient age. Survival rate of patients with liver metastasis increases quickly. The reason for this phenomenon warrants further study.

Anonymous Patient Answer

Who should consider clinical trials for neoplasm metastasis?

In general, it is difficult to convince people who have a new diagnosis, such as a cancer diagnosis like lymphoma, to participate in trials; many say they are 'unaware' of trial participation requirements. In those cases where clinical trials are available, the most important factors are: a clinical trial of interest for the person, and the extent to which their condition is similar to other people participating in the trial. In a large clinical cancer trials, there is an ongoing'match' process in which doctors seek matched patients, that are more similar in medical and socio-economic conditions. Even if people don't have the right indication or want to participate, the trial team may still offer them to be involved.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Neoplasm Metastasis by sharing your contact details with the study coordinator.